Michael Rossi, the current CEO of Y-mAbs Therapeutics, has had a significant career in the radiopharmaceutical industry, spanning over 30 years. He holds a Bachelor of Science in Pharmacy from the University of the Sciences and is a certified nuclear...

Michael Rossi, the current CEO of Y-mAbs Therapeutics, has had a significant career in the radiopharmaceutical industry, spanning over 30 years. He holds a Bachelor of Science in Pharmacy from the University of the Sciences and is a certified nuclear pharmacist. Before joining Y-mAbs in November 2023, he was the Medical Group President at Mirion Technologies, where he started in October 2022. His experience includes leadership roles at Novartis, Jubilant Pharma, and GE Healthcare, showcasing his deep understanding of pharmaceuticals and imaging technologies. He has served on various boards, bringing additional expertise to his roles. At Mirion, he was compensated with a salary of just over $106,000 and earned performance bonuses, stock options, and other benefits. Michael is known for his strategic vision and ability to drive growth within companies. Always focused on achieving performance goals, he has extensive knowledge in both corporate management and the technical aspects of his field, giving him a well-rounded perspective in his leadership roles.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Y-mAbs Therapeutics, Inc. CEOs

Y

Michael Rossi

CEO of Y-mAbs Therapeutics, Inc.

Education

Bachelor of Science in Pharmacy

Sector of Economy

Healthcare

Born

January 1, 1972 - 53 years ago

CEO of Y-mAbs Therapeutics, Inc. for

1 year 7 months (Nov 2023 - Present)

Previous Experience

Most recently served as Medical Group President of Mirion Technologies, Inc., and has over 30 years of experience in the radiopharmaceutical industry.

Rivals

Competitors/colleagues of Michael Rossi

Holdings

See how much did Michael Rossi make over time.

Michael Rossi joined Mirion Technologies in October 2022 and held the Medical Group President position until November 2023. While at Mirion, he received restricted stock units (RSUs) that began vesting on November 1, 2022. By the end of 2022, he...

Michael Rossi joined Mirion Technologies in October 2022 and held the Medical Group President position until November 2023. While at Mirion, he received restricted stock units (RSUs) that began vesting on November 1, 2022. By the end of 2022, he held 80,445 RSUs valued at over $531,000 based on the stock price at that time. Since joining Y-mAbs, the transition from Mirion marks a significant shift in his career, as he takes on new responsibilities as CEO. His previous holdings in Mirion illustrate a solid investment backing based on his growing wealth in the field, which likely reflects positive trends in the radiopharmaceutical market.

Loading...

Insider Trading

See recent insider trades of Michael Rossi.

YMAB

105,300 shares

YMAB

Jan 17, 2025

Received

YMAB

35,700 shares

YMAB

Feb 12, 2024

Received

MIR

41,242 shares

MIR

Mar 29, 2023

Received

CWT

$76.14K

CWT at $25.17/share

Mar 1, 2016

Received

CWT

$77.69K

CWT at $34.87/share

Mar 1, 2011

Purchase

Compensation History

See how much did Michael Rossi make over time.

Michael Rossi's compensation as CEO reflects his significant responsibilities and experience. In 2022, his salary at Mirion Technologies was $106,955, with the opportunity for a performance-based bonus that could reach up to 120% of his base salary. Additionally, he was awarded RSUs valued at approximately $531,741, which vest in four equal installments over four years. This pay structure aligns his interests with the company's performance, aiming to motivate him toward achieving set corporate goals. Following his transition to Y-mAbs, Rossi's new employment agreement outlines an initial base salary of $705,600, along with a signing bonus of $300,000 and eligibility for an annual cash bonus of up to 65% of his base salary. Overall, his compensation plan is designed to reward both short-term performance and long-term growth.

Year

2023

Total Compensation

$1.08M

Salary

$705.60K

Board Justification

Our compensation philosophy is designed to attract, retain, and motivate superior executive talent, providing incentives that reward the achievement of performance goals that directly correlate to the enhancement of stockholder value.

Bonus

$71.62K

Board Justification

Mr. Rossi's cash incentive bonus for 2023 was paid at the target amount and prorated based on days worked within the year, conditioned on continuous employment with the Company through December 31, 2023.

Other

$300.00K

Board Justification

Mr. Rossi received a sign-on bonus of $300,000, which was earned and paid in November 2023.

Restricted Stock

$0.00(0 N/A)

Board Justification

No stock was vested in 2023 as Mr. Rossi joined the Company in November 2023 and no stock grants were made prior to that.

Performance Metrics

The performance metrics for Mr. Rossi's compensation were based on the achievement of corporate performance objectives for 2023.

Other Y-mAbs Therapeutics, Inc. CEOs

Here are other CEOs of Y-mAbs Therapeutics, Inc.

Thomas Gad

Founder and Ex-CEO of Y-mAbs Therapeutics, Inc.

April 2022 - November 2023